Westerkirk Capital Inc. Increases Holdings in Johnson & Johnson $JNJ

Westerkirk Capital Inc. increased its stake in Johnson & Johnson (NYSE:JNJ) by 14.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 40,059 shares of the company’s stock after purchasing an additional 5,000 shares during the quarter. Johnson & Johnson comprises about 0.8% of Westerkirk Capital Inc.’s holdings, making the stock its 26th largest position. Westerkirk Capital Inc.’s holdings in Johnson & Johnson were worth $8,290,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the stock. Blueline Advisors LLC purchased a new position in Johnson & Johnson during the fourth quarter worth about $25,000. Abich Financial Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the third quarter worth about $26,000. Cresta Advisors Ltd. bought a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $26,000. DecisionPoint Financial LLC raised its stake in Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after purchasing an additional 75 shares in the last quarter. Finally, Family CFO Inc purchased a new stake in Johnson & Johnson in the fourth quarter valued at approximately $31,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Down 0.3%

Shares of JNJ stock opened at $232.17 on Tuesday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The business has a 50-day moving average price of $231.83 and a two-hundred day moving average price of $226.38. Johnson & Johnson has a 12-month low of $149.04 and a 12-month high of $251.71. The firm has a market cap of $558.89 billion, a P/E ratio of 26.84, a price-to-earnings-growth ratio of 2.28 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $24.06 billion during the quarter, compared to analyst estimates of $23.60 billion. During the same quarter in the previous year, the company posted $2.77 earnings per share. The company’s revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.3%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is presently 61.97%.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson agreed to buy Firefly Bio for $1 billion, adding a novel degrader antibody conjugate platform that could broaden its oncology pipeline and improve its position in difficult-to-treat cancers. Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
• Positive Sentiment: The Firefly deal signals continued capital deployment into high-value cancer assets, which can support investor confidence in J&J’s long-term earnings growth beyond its core healthcare franchise. Johnson & Johnson to buy Firefly Bio for $1 billion
• Neutral Sentiment: Commentary highlighting J&J as a “cheap robotics stock” focused on coronary artery disease treatment may reinforce the company’s medical technology story, but it is not a major new catalyst on its own. Johnson & Johnson (JNJ): A Cheap Robotics Stock Redefining Coronary Artery Disease Treatment
• Neutral Sentiment: A separate mention that J&J received a buy rating from Guggenheim may be supportive, but the note appears older and less likely to be driving today’s move. Johnson & Johnson (JNJ) Gets a Buy from Guggenheim

Analysts Set New Price Targets

A number of equities analysts have commented on JNJ shares. Stifel Nicolaus boosted their price target on shares of Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, April 15th. Guggenheim boosted their price target on shares of Johnson & Johnson from $244.00 to $266.00 and gave the stock a “buy” rating in a research note on Monday, April 20th. JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 15th. Royal Bank Of Canada reissued an “outperform” rating and issued a $265.00 price target on shares of Johnson & Johnson in a research note on Wednesday, April 15th. Finally, Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Twenty equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $253.04.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.